Full Text
PMS45 - COST PER RESPONDER ANALYSIS FOLLOWING A 48-WEEK PSORIATIC ARTHRITIS TREATMENT WITH SECUKINUMAB VERSUS ADALIMUMAB FROM THE PORTUGUESE PAYER PERSPECTIVE

Abstract

Authors

C. Silva J. Esparteiro A. Fonseca P.A. Laires

Back to Volume 21, Supplemental S3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×